Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling. (October 2020) - Bendell, J.; Ulahannan, S.; Koczywas, M.; Brahmer, J.; Capasso, A.; Eckhardt, S.G.; Gordon, M.; McCoach, C.; Nagasaka, M.; Ng, K.; Pacheco, J.; Riess, J.; et al.